Skip to main content
HR 2374 116th Congress House Health Administrative law and regulatory procedures Business ethics Civil actions and liability Competition and antitrust Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Licensing and registrations Public participation and lobbying

Stop STALLING Act

Introduced: April 29, 2019 Introduced by: Jeffries, Hakeem S. Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 24, 2020
Placed on the Union Calendar, Calendar No. 577.
Dec 24, 2020
Reported by the Committee on Judiciary. H. Rept. 116-694.
Apr 30, 2019
Ordered to be Reported by Voice Vote.
Apr 30, 2019
Committee Consideration and Mark-up Session Held.
Apr 29, 2019
Introduced in House
Apr 29, 2019
Referred to the House Committee on the Judiciary.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
What's happening now December 24, 2020

Placed on the Union Calendar, Calendar No. 577.

 Related & companion bills 2
  • S 1224 Related bill Stop STALLING Act
  • S 3384 Related bill Lowering Prescription Drug Prices for America’s Seniors and Families Act of 2020
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 7
All 7 Democratic 3
Posey, Bill
· Dec 9, 2019
 D
Cohen, Steve
Tennessee · Apr 30, 2019
Cicilline, David
· Apr 29, 2019
Collins, Doug
· Apr 29, 2019
 D
Nadler, Jerrold
New York · Apr 29, 2019
SENSENBRENNER, F.
· Apr 29, 2019
 D
Welch, Peter
Vermont · Apr 29, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2374: Stop STALLING Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-2374/
MLA
"H.R. 2374: Stop STALLING Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-2374/.
Bluebook (legal)
H.R. 2374, 116th Cong. (2026), https://openamerica.io/bill/116-HR-2374/.
Markdown link
[H.R. 2374: Stop STALLING Act](https://openamerica.io/bill/116-HR-2374/)
Report a problem